Compare TPH & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TPH | LQDA |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.4B |
| IPO Year | 2012 | 2020 |
| Metric | TPH | LQDA |
|---|---|---|
| Price | $46.99 | $58.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $46.67 | $41.00 |
| AVG Volume (30 Days) | ★ 2.1M | 1.4M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | 0.08 | ★ 0.52 |
| Revenue | ★ $3,260,447,000.00 | $158,320,000.00 |
| Revenue This Year | N/A | $278.87 |
| Revenue Next Year | $10.20 | $57.13 |
| P/E Ratio | $586.88 | ★ $109.35 |
| Revenue Growth | 5.76 | ★ 1031.18 |
| 52 Week Low | $28.72 | $11.85 |
| 52 Week High | $46.99 | $59.75 |
| Indicator | TPH | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 66.98 | 79.16 |
| Support Level | $46.24 | $30.48 |
| Resistance Level | $46.99 | N/A |
| Average True Range (ATR) | 0.04 | 3.45 |
| MACD | -0.05 | 1.64 |
| Stochastic Oscillator | 77.78 | 93.50 |
Tri Pointe Homes Inc is an American construction company that focuses on residential construction. The company is engaged in the design, construction, and sale of single-family attached and detached homes in different states across the United States. Its operations are organized into two principal businesses: homebuilding. which generates key revenue, and financial services. The homebuilding business has three reportable operating segments, based on the geographical layout of the markets, and includes West region, Central region, and East region. Its financial services operation is comprised of its Tri Pointe Connect mortgage financing operations, Tri Pointe Assurance title and escrow services operations, and Tri Pointe Advantage property and casualty insurance agency operations.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.